Eric Venker
President at ROIVANT SCIENCES LTD.
Net worth: 5 M $ as of 2024-03-30
Profile
Currently, Eric Venker is Co-President & Chief Operating Officer at Roivant Sciences Ltd., President & Chief Operating Officer for Roivant Sciences, Inc. and Co-President & Chief Operating Officer at Roivant Sciences GmbH (both are subsidiaries of Roivant Sciences Ltd.) and Co-President & Chief Operating Officer at Montes Archimedes Acquisition Corp. Eric Venker is also on the board of Arbutus Biopharma Corp., Sio Gene Therapies, Inc., Aruvant Sciences, Inc. and Immunovant, Inc. He previously held the position of Chairman-Housestaff Quality Council at Columbia University Medical Center. Eric Venker received a doctorate from Yale School of Medicine and a doctorate from St. Louis College of Pharmacy.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ROIVANT SCIENCES LTD.
0.06% | 2024-04-19 | 484,200 ( 0.06% ) | 5 M $ | 2024-03-30 |
Eric Venker active positions
| Companies | Position | Start |
|---|---|---|
| IMMUNOVANT, INC. | Director/Board Member | 2020-02-17 |
| ROIVANT SCIENCES LTD. | President | 2020-12-31 |
Roivant Sciences, Inc.
 Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY. | President | 2020-12-31 |
Aruvant Sciences, Inc.
 Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Aruvant Sciences, Inc. operates as a clinical-stage biopharmaceutical company. The firm develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning. It's lead candidate ARU-1801, is a modified fetal hemoglobin gene therapy for sickle cell disease and related hemoglobinopathies. The company is headquartered in New York, NY. | Director/Board Member | - |
Roivant Sciences GmbH
 Roivant Sciences GmbH Pharmaceuticals: MajorHealth Technology Roivant Sciences GmbH engages in the development and marketing of biopharmaceutical products. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in Basel, Switzerland. | Chief Operating Officer | - |
| Roivant Social Ventures, Inc. | Director/Board Member | 2013-12-31 |
Former positions of Eric Venker
| Companies | Position | End |
|---|---|---|
| SIO GENE THERAPIES INC. | Director/Board Member | 2023-04-04 |
| ARBUTUS BIOPHARMA CORPORATION | Director/Board Member | 2022-05-24 |
| ROIVANT SCIENCES LTD. | President | - |
| ░░░░░░░░ ░░░░░░░░░░ ░░░░░░░ ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Training of Eric Venker
| St. Louis College of Pharmacy | Doctorate Degree |
| Yale School of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| ARBUTUS BIOPHARMA CORPORATION | Health Technology |
| ROIVANT SCIENCES LTD. | Health Technology |
| IMMUNOVANT, INC. | Health Technology |
| Private companies | 6 |
|---|---|
Roivant Sciences GmbH
Roivant Sciences GmbH Pharmaceuticals: MajorHealth Technology Roivant Sciences GmbH engages in the development and marketing of biopharmaceutical products. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in Basel, Switzerland. | Health Technology |
Sio Gene Therapies, Inc.
 Sio Gene Therapies, Inc. Pharmaceuticals: MajorHealth Technology Sio Gene Therapies, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. The company was founded on October 31, 2014 and is headquartered in New York, NY. | Health Technology |
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY. | Health Technology |
Aruvant Sciences, Inc.
Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Aruvant Sciences, Inc. operates as a clinical-stage biopharmaceutical company. The firm develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning. It's lead candidate ARU-1801, is a modified fetal hemoglobin gene therapy for sickle cell disease and related hemoglobinopathies. The company is headquartered in New York, NY. | Health Technology |
Montes Archimedes Acquisition Corp.
 Montes Archimedes Acquisition Corp. Financial ConglomeratesFinance Montes Archimedes Acquisition Corp operates as a blank check company. It is formed for the business purpose to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded James C. Momtazee and Maria C. Walker on July 6, 2020 and is headquartered in Menlo Park, CA. | Finance |
| Roivant Social Ventures, Inc. |
- Stock Market
- Insiders
- Eric Venker
